Prognostic implication of right ventricular dysfunction and tricuspid regurgitation following transcatheter aortic valve replacement

Objectives Right ventricular (RV) dysfunction and tricuspid regurgitation (TR) are associated with adverse outcomes in severe aortic stenosis (AS) patients. Our aim was to evaluate the association between >= moderate TR and RV dysfunction on long-term mortality following transcatheter aortic valve replacement (TAVR). Methods A retrospective analysis of the Israeli multicenter TAVR registry among 4,344 consecutive patients, with all-cause mortality as the main outcome measure. Results Echocardiographic assessment of TR grade and RV dysfunction was available for 3,733 and 1,850 patients, of whom >= moderate TR and RV dysfunction was noted for 478(13%) and 78(4%), respectively. The mean follow-up time was 2.9 +/- 2.3 years. In univariate models, >= Moderate TR and >= moderate RV dysfunction were associated with increased long-term mortality (HR 1.45, 95% CI 1.24-1.69, p < .001 and HR 1.73, 95% CI 1.21-2.47, p = 0.003, respectively). These finding did not remained significant after adjusting to echocardiographic parameters. A subset of patients with no improvement in RV function had the highest long-term mortality risk (HR 3.3, 95% CI 1.95-5.7, p < .001). Conclusion When adjusted to multiple echocardiographic characteristics baseline >= Moderate TR and >= moderate RV dysfunction were not associated with long-term mortality following TAVR. Persistent RV dysfunction following TAVR was associated with the highest risk for mortality.

Automated summary

This study evaluated the association between >= moderate tricuspid regurgitation (TR) and right ventricular (RV) dysfunction with long-term mortality following transcatheter aortic valve replacement (TAVR). The findings showed that persistent RV dysfunction after TAVR was associated with the highest risk for mortality. Adjusted for multiple echocardiographic characteristics, baseline TR and RV dysfunction were not associated with long-term mortality following TAVR.